Development and Characterization of Gastroretentive Drug Delivery System of Olmesartan Medxomil
Abstract
The objective of the study was to develop an optimized gastro retentive drug delivery system of Olmesartan Medoxomil. The tablets were formulated by direct compression using HPMC K15M, HPMC K4M, Xanthan Gum and PVP K30. Sodium bicarbonate was used as the gas generating agent to reduce the floating lag time. The drug-polymer interaction was evaluated by Fourier Transform Infrared Spectroscopy (FTIR) and DSC study. The FTIR and DSC study indicated the lack of drug-polymer interaction. The formulated tablets were evaluated for hardness, weight variation, thickness, floating capacity, swelling index, drug content, in vitro dissolution study. Formulations were following nonfickian (anamalous) diffusion as the release mechanism from all the floating tablets prepared with various polymers.
Keywords:
Gastroretentive drug delivery system, Anti-hypertensive, Olmesartan Medxomil, HPMC K15M, HPMC K4M, Xanthan GumDOI
https://doi.org/10.25004/IJPSDR.2021.130217References
Thanoo BC, Sunny MC, Jayakrishnan A. Oral Sustained‐release Drug Delivery Systems using Polycarbonate Microspheres Capable of Floating on the Gastric Fluid. Journal of Pharmacy and Pharmacology. 1993; 45(1):21-24.
Ankit B, Rathore RP, Tanwar YS, Gupta S, Bhaduka G. Oral sustained release dosage form: an opportunity to prolong the release of drug. International Journal of Advanced Research in Pharmaceutical & Bio Sciences. 2013; 3(1):7-14.
Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Development and Industrial Pharmacy. 1996; 22(6):531-539.
Kumar KS, Bhowmik D, Srivastava S, Paswan S, Dutta AS. Sustained release drug delivery system potential. The pharma innovation. 2012; 1(2):48-60.
Dixit N, Maurya SD, Sagar BP. Sustained release drug delivery system. Indian Journal of Research in Pharmacy and Biotechnology. 2013;1(3):305-310.
Zalte HD, Saudagar RB. Review on sustained release matrix tablet. International Journal of Pharmacy and Biological Sciences. 2013; 3(4):17-29.
Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Development and Industrial Pharmacy. 1996; 22(6):531-539.
Jaimini M, Kothari AH. Sustained release matrix type drug delivery system: a review. Journal of Drug Delivery and Therapeutics. 2012; 2(6):142-148.
Mandhar P, Joshi G. Development of sustained release drug delivery system: A review. Asian Pac. J. Health Sci. 2015; 2(1):179-185.
Kumar AR, Aeila ASS. Sustained release matrix type drug delivery system: An overview. World J. Pharm. Pharm. 2019; 9:470-480.
Kumar R, Philip A. Gastroretentive dosage forms for prolonging gastric residence time. International Journal of Pharmaceutical Medicine. 2007; 21(2):157-171.
Garg T, Kumar A, Rath G, Goyal AK. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2014; 31(6): 531- 557.
El-Gamal MI, Anbar HS, Chung HJ, Kim HI, Cho YJ, Lee BS, Lee SA, Moon JY, Lee DJ, Kwon D, Choi WJ. Discovery of olmesartan hexetil: a new potential prodrug of olmesartan. Bioorganic & Medicinal Chemistry Letters. 2013; 23(5):1347-1350.
Nussberger J, Koike H. Antagonizing the angiotensin II subtype I receptor: A focus on olmesartan medoxomil. Clinical therapeutics. 2004;26:A12-A20.
Barrios V, Boccanelli A, Ewald S, Girerd X, Heagerty A, Krzesinski JM, Lins R, Rodicio J, Stefenelli T, Woittiez A, Böhm M. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension. Clinical Drug Investigation. 2007; 27(8):545-558.
Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. Journal of Human Hypertension. 2002; 16(2):S13-S16.
Warner GT, Jarvis B. Olmesartan medoxomil. Drugs, 2002; 62(9):1345-1353.
Verma PK, Kamboj VK HPTLC method for estimation of Olmesartan medoxomil in tablet formulation with stability studies. Pakistan Journal of Pharmaceutical Sciences. 2013; 26(1): 209-215.
Al Masud A, Rahman MM, Hasan M, Ripon MKH, Khan AR, Islam MR, Sarkar MR. Validated spectrophotometric method for estimation of olmesartan medoxomil in pharmaceutical formulation. International Journal of Pharmaceutical and Life Sciences, 2012, 1(3); 1-7.
Government of India, Ministry of Health. Pharmacopoeia of India: (the Indian Pharmacopoeia). Delhi: Manager of Publications, 2010.
Bahadur S, Roy A, Baghel P, Choudhury A, Saha S, Chanda R. Formulation and evaluation of glipizide tablets utilizing Hibiscus rosasinensis leaves mucilage. Indonesian Journal of Pharmacy. 2018; 29(1):23-28.
Bahadur S, Roy A, Chanda R, Baghel P, Saha S, Choudhury A. Assessment of Some Phytochemcial and Physicochemical Properties of Fenugreek Seed Mucilage. Research Journal of Pharmacy and Technology. 2016; 9(9):1321-1324.
Strübing S, Metz H, Mäder K. Characterization of poly (vinyl acetate) based floating matrix tablets. Journal of controlled release. 2008; 126(2):149-155.
Nerurkar J, Jun HW, Price JC, Park MO. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. European Journal of Pharmaceutics and Biopharmaceutics. 2005; 61(1-2):56-68.
Sruthy PN, Anoop KR Formulation and evaluation of olmesartan medoxomil floating tablets. Int J Pharm Pharm Sci. 2013; 5(3):691- 696.
Mosgoeller W, Prassl R, Zimmer A. Nanoparticle-mediated treatment of pulmonary arterial hypertension. Methods in enzymology. 2012; 508:325-354.
Clayton J. An Introduction to Powder Characterization. In Handbook of Pharmaceutical Wet Granulation 2019; (pp. 569-613). Academic Press.
El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral delivery system. International Journal of Pharmaceutics. 2001; 220(1-2):13-21.
Rajinikanth P. Preparation and in vitro characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. pylori. Acta Pharmaceutica. 2007; 57(4):413-427.
Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. Aaps PharmSciTech. 2004; 5(2):77-82.
Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers. Journal of Controlled Release. 2003; 93(1):39-47.
Published
Abstract Display: 469 
PDF Downloads: 399 
